-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target

Benzinga·05/06/2026 15:49:28
Listen to the news
RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.